Allopurinol Can Cause Thrombocytopenia, Though It Is Rare
Yes, allopurinol can cause thrombocytopenia as part of bone marrow suppression, though this is an uncommon adverse effect. The FDA drug label explicitly lists thrombocytopenia under hematologic adverse reactions with an incidence of less than 1% 1.
Mechanism and Clinical Presentation
Allopurinol-induced thrombocytopenia typically occurs as part of broader bone marrow depression affecting multiple cell lines (pancytopenia), rather than isolated thrombocytopenia. The FDA label warns that bone marrow depression has been reported in patients receiving allopurinol, occurring as early as 6 weeks to as long as 6 years after initiation 1. This can manifest as:
- Isolated thrombocytopenia
- Pancytopenia (affecting all three cell lines)
- Part of DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms)
Risk Factors
Several factors increase the risk of allopurinol-induced hematologic toxicity:
- Renal impairment: The incidence of adverse reactions, including thrombocytopenia, may be increased in patients with decreased renal function 1. This occurs because oxypurinol (allopurinol's active metabolite) accumulates when renal clearance is impaired 1
- Concurrent thiazide diuretics: The combination may enhance allopurinol toxicity 1
- Drug interactions: Concomitant use with azathioprine or mercaptopurine dramatically increases bone marrow suppression risk 1, 2, 3
Clinical Evidence
Multiple case reports document allopurinol-induced thrombocytopenia and pancytopenia:
- A 2020 case reported severe thrombocytopenia (platelets 1,000/mm³) with pancytopenia in a patient on allopurinol for 7 months, ultimately fatal despite treatment 4
- Another 2020 case described thrombocytopenia (140,000/mm³) as part of DRESS syndrome occurring 35 days after starting allopurinol 5
- A 2009 case documented pancytopenia in a patient with chronic kidney disease after 5 months of allopurinol therapy 6
Critical Drug Interactions
When allopurinol is given with azathioprine or mercaptopurine, the dose of these immunosuppressants must be reduced to 25-33% of the usual dose 1, 3. Failure to do so can result in profound, potentially fatal pancytopenia. This interaction is particularly relevant in transplant patients who may develop gout 2.
Monitoring and Management
The FDA label recommends:
- Immediate discontinuation at the first sign of bone marrow suppression 1
- Periodic monitoring of complete blood counts, particularly in patients with renal impairment or concurrent illnesses affecting renal function 1
- Starting at low doses (100 mg daily) and titrating gradually, especially in patients with renal impairment 7
Comparison to Other Adverse Effects
While thrombocytopenia is rare (incidence <1%), it is less common than:
- Skin rash (the most frequent adverse reaction, though also <1% with current usage) 1
- Allopurinol hypersensitivity syndrome (AHS), which has an incidence of approximately 7.0/1000 patient-years with a 25-30% mortality rate 7
Clinical Implications
Thrombocytopenia from allopurinol is a serious but uncommon adverse effect that requires immediate drug discontinuation and supportive care. The risk is substantially elevated in patients with renal impairment and those taking interacting medications. Healthcare providers must maintain vigilance for hematologic toxicity, particularly during the first 6 months of therapy, and ensure appropriate dose adjustments in renal disease. When thrombocytopenia occurs, it often presents as part of pancytopenia and may require treatment with growth factors (G-CSF, romiplostim) and blood product support 2, 4, 8.